



**Richard Gutowski**

07/05/2004 11:12

Him 17

To: Geoff Rees/NUR-PS/DOH/GB@GRO-C  
cc: Julia Stallibrass/POLICY/DOH/GB@GRO-C  
Seedat/PH6/DOH/GB@GRO-C David Daley/COMMS/DOH/GB@GRO-C  
Subject: URGENT: Draft letter to Finance Branch, DH

Geoff

Please see the attached. Grateful for your permission to proceed as indicated.

On a linked matter. I sent you a minute querying the fact that the recombinant allocation for this year had been cut by £4m. I would be grateful for confirmation that this is in fact the case so I can ask for the PCT allocations to be re calculated. I will also need to inform Melanie Johnson as she wanted some sort of media activity when the allocation letters were sent out. The fact that we will £4m short of what Ministers have publicly stated will go out this year slightly takes the gloss off this good news story.

Richard

----- Forwarded by Richard Gutowski/PH6/DOH/GB on 07/05/2004 10:59 -----

**Julia Stallibrass**

04/05/2004 13:05

To: Richard Gutowski/PH6/DOH/GB@GRO-C  
cc: FRANK.HILL@GRO-C  
bcc:  
Subject: URGENT: Draft letter to Finance Branch, DH

Richard - What do you think of the draft letter below. If happy, do you want to send it to the appropriate persons in Finance? Julia

DRAFT EMAIL TO FINANCE BRANCH:

The roll out of the recombinant clotting products programme in 2003/04, 2005/06 is causing PCTs and their LSCGs some concerns. Apparently, auditors have queried the fact that commissioners are being asked to:

1. Fund providers to hold a stock of recombinant clotting products. (Holding stock is actually regarded as good clinical practice by the United Kingdom Haemophilia Centres' Doctors' Organisation to ensure that a provider never runs out of products. We can get a letter from UKHCDO to this effect if needed.)
2. Fund stock from 2003/04 (or 2004/05 budgets) which will be used in 2004/05 (or 2003/06).
3. Fund providers in advance of use (i.e. before treatment rather than after treatment as is the norm).

It would be very helpful to have a letter from the DH advising that in the context of Recombinant Clotting Products Roll-Out the above behaviour is entirely proper. I attach below a draft letter for your comments.

Would such a note be best from you or from us on the basis of "your advice"? Please advise.

Richard Gutowski

*DRAFT LETTER FROM DH TO COMMISSIONERS OF HAEMOPHILIA SERVICES*

*Dear Colleagues*

*Roll Out of the Recombinant Clotting Products Programme, 2003-2006.*

*To successfully progress the roll out of the recombinant clotting products programme, 2003-2006, it will be necessary for commissioners of haemophilia services to:*

- 1. Fund a stock of recombinant clotting products for specialised patients which may be held by haemophilia service providers, the suppliers or a third party. (See note below.)*
- 2. Fund a stock of recombinant clotting products for specialised patients in 2003/04 or 2004/05 some of which may not be used until 2004/05 or 2005/06 respectively.*
- 3. Fund providers to provide recombinant clotting products to specified patients for a specialised time period in the future.*

*a DH official*

*Branch Name*

*Date*

*Note:*

*The United Kingdom Haemophilia Centres' Doctors' Organisation states that holding a stock of clotting products is regarded as good clinical practice as it reduces the likelihood of running out of particular product to the detriment of patient care.*